No Data
No Data
Essa Pharma Is Maintained at Outperform by Oppenheimer
Essa Pharma Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on ESSA Pharma, Maintains $17 Price Target
ESSA Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 191.1% Oppenheimer $17 → $17 Maintains Outperform 12/13/2023 191.1% Oppenheimer → $17 Reiterate
Oppenheimer Sticks to Its Buy Rating for ESSA Pharma (EPIX)
Buy Rating Endorsed for ESSA Pharma on Robust Pipeline and Market Expansion Potential
ESSA Pharma's Promising Prostate Cancer Trial Updates